SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

30 Jan 2024 Evaluate
The sales for the December 2023 quarter moved up 34.54% to Rs. 5200.15 millions as compared to Rs. 3865.14 millions during the corresponding quarter last year.Net profit was down at Rs. 25.42  millions against Rs. 125.36 millions recorded in the corresponding quarter a year ago.The net profit spiraled down by -79.72%.A decline of 743.41 millions was observed in the OP in the quarter ended December 2023 from 753.57 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 5200.15 3865.14 34.54 15356.26 12909.39 18.95 18544.96 19790.03 -6.29
Other Income 86.86 297.52 -70.81 426.72 576.88 -26.03 840.66 1234.85 -31.92
PBIDT 743.41 753.57 -1.35 2071.57 367.30 464.00 1825.43 2001.15 -8.78
Interest 444.67 351.04 26.67 1211.62 957.81 26.50 1386.82 742.41 86.80
PBDT 245.83 402.53 -38.93 807.04 -590.51 -236.67 288.61 1258.74 -77.07
Depreciation 210.63 222.62 -5.39 638.61 709.09 -9.94 936.21 1043.66 -10.30
PBT 35.20 179.91 -80.43 168.43 -1299.60 -112.96 -647.60 215.08 -401.10
TAX 9.78 54.55 -82.07 50.16 -722.45 -106.94 -694.42 -1586.80 -56.24
Deferred Tax 3.03 128.08 -97.63 18.76 -454.11 -104.13 -195.99 -2.09 9277.51
PAT 25.42 125.36 -79.72 118.27 -577.15 -120.49 46.82 1801.88 -97.40
Equity 918.86 903.33 1.72 918.86 903.33 1.72 903.03 897.90 0.57
PBIDTM(%) 14.30 19.50 -26.67 13.49 2.85 374.14 9.84 10.11 -2.66

Strides Pharma Scien Share Price

1000.65 4.30 (0.43%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×